SEARCH

SEARCH BY CITATION

References

  • 1
    Ford D,Easton DF,Stratton M,Narod S,Goldgar D,Devilee P,Bishop DT,Weber B,Lenoir G,Chang-Claude J,Sobol H,Teare MD, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998; 62: 67689.
  • 2
    Antoniou A,Pharoah PD,Narod S,Risch HA,Eyfjord JE,Hopper JL,Loman N,Olsson H,Johannsson O,Borg A,Pasini B,Radice P, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 111730.
  • 3
    Hartmann LC,Sellers TA,Schaid DJ,Frank TS,Soderberg CL,Sitta DL,Frost MH,Grant CS,Donohue JH,Woods JE,McDonnell SK,Vockley CW, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001; 93: 16337.
  • 4
    Eisen A,Lubinski J,Klijn J,Moller P,Lynch HT,Offit K,Weber B,Rebbeck T,Neuhausen SL,Ghadirian P,Foulkes WD,Gershoni-Baruch R, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 2005; 23: 74916.
  • 5
    Finch A,Beiner M,Lubinski J,Lynch HT,Moller P,Rosen B,Murphy J,Ghadirian P,Friedman E,Foulkes WD,Kim-Sing C,Wagner T, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296: 18592.
  • 6
    Fisher B,Costantino JP,Wickerham DL,Redmond CK,Kavanah M,Cronin WM,Vogel V,Robidoux A,Dimitrov N,Atkins J,Daly M,Wieand S, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 1998; 90: 137188.
  • 7
    Metcalfe K,Lynch HT,Ghadirian P,Tung N,Olivotto I,Warner E,Olopade OI,Eisen A,Weber B,McLennan J,Sun P,Foulkes WD, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004; 22: 232835.
  • 8
    Warner E,Plewes DB,Hill KA,Causer PA,Zubovits JT,Jong RA,Cutrara MR,DeBoer G,Yaffe MJ,Messner SJ,Meschino WS,Piron CA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 2004; 292: 131725.
  • 9
    Kriege M,Brekelmans CT,Boetes C,Besnard PE,Zonderland HM,Obdeijn IM,Manoliu RA,Kok T,Peterse H,Tilanus-Linthorst MM,Muller SH,Meijer S, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004; 351: 42737.
  • 10
    Leach MO,Boggis CR,Dixon AK,Easton DF,Eeles RA,Evans DG,Gilbert FJ,Griebsch I,Hoff RJ,Kessar P,Lakhani SR,Moss SM, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 176978.
  • 11
    Lynch H,Lemon S,Durham C,Tinley S,Connolly C,Lynch J,Surdam J,Orinion E,Slominski-Caster S,Watson P,Lerman C,Tonin P, et al. A descriptive study of BRCA1 testing and reactions to desclosure of test results. Cancer 1997; 79: 221928.
  • 12
    Metcalfe KA,Liede A,Hoodfar E,Scott A,Foulkes WD,Narod SA. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. J Med Genet 2000; 37: 86674.
  • 13
    Lodder LN,Frets PG,Trijsburg RW,Meijers-Heijboer EJ,Klijn JG,Seynaeve C,van Geel AN,Tilanus MM,Bartels CC,Verhoog LC,Brekelmans CT,Burger CW, et al. One year follow-up of women opting for presymptomatic testing for BRCA1 and BRCA2: emotional impact of the test outcome and decisions on risk management (surveillance or prophylactic surgery). Breast Cancer Res Treat 2002; 73: 97112.
  • 14
    Wagner TM,Moslinger R,Langbauer G,Ahner R,Fleischmann E,Auterith A,Friedmann A,Helbich T,Zielinski C,Pittermann E,Seifert M,Oefner P. Attitude towards prophylactic surgery and effects of genetic counselling in families with BRCA mutations. Austrian Hereditary Breast and Ovarian Cancer Group. Br J Cancer 2000; 82: 124953.
  • 15
    Lerman C,Hughes C,Croyle RT,Main D,Durham C,Snyder C,Bonney A,Lynch JF,Narod SA,Lynch HT. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000; 31: 7580.
  • 16
    Phillips KA,Jenkins MA,Lindeman GJ,McLachlan SA,McKinley JM,Weideman PC,Hopper JL,Friedlander ML. Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 2006; 70: 198206.
  • 17
    Hartmann LC,Schaid DJ,Woods JE,Crotty TP,Myers JL,Arnold PG,Petty PM,Sellers TA,Johnson JL,McDonnel SK,Frost MH,Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999; 340: 7785.
  • 18
    Meijers-Heijboer M,VanGeel B,VanPutten W,Henzen-Logmans S,Seynaeve C,Menke-Pluymers M,Bartels C,Verhoog L,VanDenOuweland A,Niermeijer M,Brekelmans T,Klijn J. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345: 15864.
  • 19
    Narod SA,Brunet JS,Ghadirian P,Robson M,Heimdal K,Neuhausen SL,Stoppa-Lyonnet D,Lerman C,Pasini B,de los Rios P,Weber B,Lynch H. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 2000; 356: 187681.
  • 20
    Metcalfe KA,Esplen MJ,Goel V,Narod S. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004; 13: 1425.
  • 21
    Metcalfe KA,Snyder C,Seidel J,Hanna D,Lynch HT,Narod S. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005; 4: 97103.
  • 22
    Schwartz MD,Kaufman E,Peshkin BN,Isaacs C,Hughes C,DeMarco T,Finch C,Lerman C. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003; 21: 403441.
  • 23
    Botkin JR,Smith KR,Croyle RT,Baty BJ,Wylie JE,Dutson D,Chan A,Hamann HA,Lerman C,McDonald J,Venne V,Ward JH, et al. Genetic testing for a BRCA1 mutation: prophylactic surgery and screening behavior in women 2 years post testing. Am J Med Genet 2003; 118A: 2019.
  • 24
    Meijers-Heijboer EJ,Verhoog LC,Brekelmans CT,Seynaeve C,Tilanus-Linthorst MM,Wagner A,Dukel L,Devilee P,van den Ouweland AM,van Geel AN,Klijn JG. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. Lancet 2000; 355: 201520.
  • 25
    Julian-Reynier CM,Bouchard LJ,Evans DG,Eisinger FA,Foulkes WD,Kerr B,Blancquaert IR,Moatti JP,Sobol HH. Women's attitudes toward preventive strategies for hereditary breast or ovarian carcinoma differ from one country to another: differences among English, French, and Canadian women. Cancer 2001; 92: 95968.
  • 26
    Metcalfe K,Ghadirian P,Rosen B,Foulkes WD,Kim-Sing C,Eisen A,Ainsworth P,Horsman D,Maugard C,Provencher D,Robidoux A,Gilchrist D, et al. Variation in rates of uptake of preventive options in BRCA1 and BRCA2 mutation carriers across Canada. Open Med 2007; 1: E92E98.
  • 27
    Houn F,Helzlsouer KJ,Friedman NB,Stefanek ME. The practice of prophylactic mastectomy: a survey of Maryland surgeons. Am J Public Health 1995; 85: 8015.
  • 28
    Julian-Reynier C,Eisinger F,Moatti JP,Sobol H. Physicians' attitudes towards mammography and prophylactic surgery for hereditary breast/ovarian cancer risk and subsequently published guidelines. Eur J Hum Genet 2000; 8: 2048.
  • 29
    Peshkin BN,Isaacs C,Finch C,Kent S,Schwartz MD. Tamoxifen as chemoprevention in BRCA1/2 carriers with breast cancer: a pilot survey of physicians. J Clin Oncol 2003; 21: 432228.
  • 30
    Saslow D,Boetes C,Burke W,Harms S,Leach MO,Lehman CD,Morris E,Pisano E,Schnall M,Sener S,Smith RA,Warner E, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007; 57: 7589.
  • 31
    Metcalfe KA,Narod SA. Breast cancer risk perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst 2002; 94: 15649.